The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS

被引:281
|
作者
Parker, JE [1 ]
Mufti, GJ [1 ]
Rasool, F [1 ]
Mijovic, A [1 ]
Devereux, S [1 ]
Pagliuca, A [1 ]
机构
[1] Guys Kings Thomas Sch Med, Dept Haematol Med, London SE5 8RX, England
关键词
D O I
10.1182/blood.V96.12.3932.h8003932_3932_3938
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bone marrow CD34(+) cell apoptosis (annexin V), proliferation (Ki-67), and Bcl-2-related protein expression was evaluated by flow cytometry in 102 patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia secondary to MDS (MDS-AML) and in 30 normal donors (NBM). Apoptosis was significantly increased in refractory anemia (RA)/RA with ringed sideroblasts (RARS) (56.9% [20.4%-93.6%]) and refractory anemia with excess blasts (RAEB) (51.2% [25.2%-76.6%]) compared with NBM (16.7% [3.4%-35.3%], P < .0001). In RA/RARS, apoptosis always exceeded proliferation (Ki-67-positivity, 26.1% [9.5%-47.8%]; apoptosis: proliferation ratio 2.08 [1.15-3.63]); whereas in RAEB, this ratio equalized (1.14 [0.93-2.08]) due to increased proliferation (40.4% [22%-69.5%]). Progression to RAEB in transformation (RAEB-t)/MDS-AML was associated with a significant reduction in apoptosis (22.3% [2.1%-53.2%]; P < .0001) and proliferation (16.8% [1.9%-75.8%] P = .04; ratio 1.69 [0.16-12.21]), Pro-apoptotic (Bax/Bad) versus anti-apoptotic (Bcl-2/Bcl-X) Bcl-2-related protein ratios were increased in RA/RARS compared with NBM (2.57 [1.93-9.42] versus 1.89 [0.65-4.1]; P = .06), whereas disease progression was associated with significantly reduced ratios (1.16 [0.06-3.32]; P < .0001) due primarily to increased Bcl-2 expression. Apoptosis and Bax/Bad:Bcl-2/Bcl-X ratio were inversely correlated with both International Prognostic Scoring System score and cytogenetic risk group; highest levels observed in patients with low score and/or good risk cytogenetics. There was a trend toward an association between Bcl-2-related protein expression and apoptosis (P = .07). This study indicates that MDS progression arises through multiple hits that alter levels of CD34(+) cell apoptosis and proliferation. Early disease is associated with excessive apoptosis and elevated ratio of apoptosis to proliferation. Increased proliferative rates are observed in RAEB, whereas leukemic transformation arises through inhibition of apoptosis rather than excessive cell growth. Although disease progression is accompanied by a fall in pro-apoptotic versus anti-apoptotic Bcl-2-related protein ratios, heterogeneity in patterns of protein expression indicates that factors additional to Bcl-2 family members play a role in the deregulated apoptosis in MDS. (C) 2000 by The American Society of Hematology.
引用
收藏
页码:3932 / 3938
页数:7
相关论文
共 50 条
  • [41] How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?
    Steensma, David P.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2021, 34 (04)
  • [42] Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS)
    Madanat, Yazan F.
    Sekeres, Mikkael A.
    Al-Issa, Karam
    Hirsch, Cassandra M.
    Mukherjee, Sudipto
    Gerds, Aaron T.
    Abuhadra, Nour
    Jha, Babal K.
    Adema, Vera
    Advani, Anjali S.
    Nagata, Yasunobu
    Kuzmanovic, Teodora
    Przychodzen, Bartlomiej P.
    Carraway, Hetty E.
    Maciejewski, Jaroslaw P.
    Nazha, Aziz
    BLOOD, 2017, 130
  • [43] Clinical significance of del(20q) in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
    Tedeschi, A
    Montillo, M
    Hayes, KJ
    Di Raimondo, F
    Lerner, S
    Morra, E
    Estey, E
    Keating, MJ
    BLOOD, 2000, 96 (11) : 709A - 709A
  • [44] Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States
    Albitar, Adam Zrinski
    Shah, Neil
    McCloskey, James K.
    Koprivnikar, Jamie L.
    Zhao, Jianhua
    Desai, Chirag
    Sudarsanam, Sucha
    Albitar, Maher
    Lai, Catherine E.
    BLOOD, 2018, 132
  • [45] Mutational analysis of the C/EBP α gene in the myelodysplastic syndromes and acute myeloid leukemia following MDS.
    Verbeek, W
    Kaeferstein, A
    Faulhaber, M
    Stadler, M
    Krauter, J
    Germing, U
    Hofmann, WK
    Koeffler, HP
    Ganser, A
    BLOOD, 2001, 98 (11) : 353A - 353A
  • [46] Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) after Multiple Myeloma: Assessment of Risk Factors
    Jonsdottir, Gudbjorg
    Bjorkholm, Magnus
    Turesson, Ingemar
    Hultcrantz, Malin
    Porwit, Anna
    Jethava, Yogesh
    Landgren, Ola
    Kristinsson, Sigurdur Y.
    BLOOD, 2017, 130
  • [47] Role of bcl-2 family proteins in phorbol ester-induced apoptosis of acute myeloid leukemia cells
    Holbert, Cassandra
    Forrester, Jeffrey
    Roberts, Michael
    CANCER RESEARCH, 2016, 76
  • [48] Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
    Wei, Yunxiong
    Cao, Yaqing
    Sun, Rui
    Cheng, Lin
    Xiong, Xia
    Jin, Xin
    He, Xiaoyuan
    Lu, Wenyi
    Zhao, Mingfeng
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [49] BLOCKADE OF BCL-2 PROTEINS EFFICIENTLY INDUCES APOPTOSIS IN PROGENITOR CELLS OF HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS
    Jilg, S.
    Reidel, V.
    Mueller-Thomas, C.
    Koenig, J.
    Schauwecker, J.
    Burgkart, R.
    Hoeckendorf, U.
    Huberle, C.
    Gorka, O.
    Ruland, J.
    Kolb, H.
    Peschel, C.
    Oostendorp, R.
    Goetze, K.
    Jost, P.
    LEUKEMIA RESEARCH, 2015, 39 : S12 - S12
  • [50] THERAPY-RELATED MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA: ETIOLOGY, PROGNOSIS AND TREATMENT
    Kujawski, E.
    Burnham, M. R.
    Mousa, S. S.
    Mousa, S. A.
    DRUGS OF THE FUTURE, 2010, 35 (03) : 219 - 236